Evaluation of Brain Metastases Treated With Stereotactic Radiotherapy Using Dynamic [18F]FDG PET
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Maureen Dougan
- Phone Number: 35352 519 685 8500
- Email: maureen.dougan@sjhc.london.on.ca
Study Contact Backup
- Name: Melody Qu
- Phone Number: 53025 519 685 8500
- Email: melody.qu@lhsc.on.ca
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 or older.
- Willing and able to provide consent.
- ECOG 0-2.
- Life expectancy ≥12 months.
- Creatinine clearance ≥30 ml/min within 28 days prior to registration.
- At the discretion of the treating oncologist, it is believed that at least 1 lesion (or resection cavity) is best managed with SRS/SFR
Exclusion Criteria:
- Pregnant or nursing women.
- Men or women of childbearing potential who are unwilling to employ adequate contraception.
- Inability to complete a brain MRI.
- Known allergy to gadolinium.
- Inability to complete a PET scan.
- Uncontrolled diabetes mellitus.
- Primary germ cell tumour, primary CNS tumour, or lymphoma
- SRS/FSRT is no longer indicated for any BMs
- Must be able to read and write English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Observational
This is a prospective, single-arm, pilot diagnostic study to evaluate the diagnostic accuracy of using dynamic [18F]FDG PET in 70 patients with brain metastases managed with stereotactic radiosurgery(SRS)/fractionated stereotactic radiotherapy (FSRT).
The study will include imaging assessments at baseline, at 10 weeks after treatment, and at first concern for progression or 12 months post-treatment, whichever comes earlier.
|
at baseline prior to stereotactic radiation, at 10 weeks after treatment, and at first concern for progression at treated lesion or 12 months post-treatment, whichever comes earlier.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic accuracy of dynamic PET
Time Frame: 12-month follow-up.
|
Diagnostic accuracy will be calculated and compared based on the index lesion.
|
12-month follow-up.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical outcomes
Time Frame: 24-month follow-up
|
Clinical outcomes such as local recurrence.
|
24-month follow-up
|
|
Clinical outcomes
Time Frame: 24-month follow-up
|
CNS progression-free survival and overall survival will be analyzed
|
24-month follow-up
|
|
Clinical outcomes
Time Frame: 24-month follow-up
|
Factors impact on these outcomes will be explored.
|
24-month follow-up
|
|
Diagnostic imaging outcomes
Time Frame: 24-month follow-up
|
GMR-to-perfusion ratio.
|
24-month follow-up
|
|
Diagnostic imaging outcomes
Time Frame: 24-month follow-up
|
Blood-brain barrier permeability to glucose.
|
24-month follow-up
|
|
Diagnostic imaging outcomes
Time Frame: 24-month follow-up
|
Glucose Metabolic Rate.
|
24-month follow-up
|
|
Diagnostic imaging outcomes
Time Frame: 24-month follow-up
|
Magnetic resonance spectroscopy data.
|
24-month follow-up
|
|
Diagnostic imaging outcomes
Time Frame: 24-month follow-up
|
Other ancillary clinical data will be explored.
|
24-month follow-up
|
|
Cost-effectiveness analysis
Time Frame: 24-month follow-up
|
A decision analysis model coupled with Markov model will be constructed to estimate the incremental cost-effectiveness ratio (ICER) of performing dynamic PET in this setting from the Canadian health-care system perspective.
|
24-month follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Radiopharmaceuticals
- Fluorodeoxyglucose F18
Other Study ID Numbers
Other Study ID Numbers
- 124854
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.